Embryonal carcinoma Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Apr 2026Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)

Hospices Civils de Lyon — PHASE2

TrialNOT YET RECRUITING

Mar 2026A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Memorial Sloan Kettering Cancer Center — PHASE1

TrialNOT YET RECRUITING

Feb 2026Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Intergroupe Francophone de Cancerologie Thoracique — PHASE3

TrialRECRUITING

Dec 2025DLL3-Targeted PET/CT in Neuroendocrine Carcinoma

The First Affiliated Hospital of Xiamen University — NA

TrialRECRUITING

Aug 2025A Community-based Educational Initiative to Raise Awareness of Melanoma and Other Skin Cancers.

NYU Langone Health — NA

TrialACTIVE NOT RECRUITING

May 2025SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)

Peter Hosein, MD — PHASE1

TrialRECRUITING

Apr 2025Single-Center Trial on Ketogenic Diet and Immunotherapy in Advanced Cancer This Study Evaluates the Safety and Effects of a Ketogenic Diet (KD) Combined With Immunotherapy in Adults With Advanced Melanoma, cSCC, or RCC.

Rabin Medical Center — PHASE1, PHASE2

TrialNOT YET RECRUITING

Jul 2024Irinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma

First Affiliated Hospital Xi'an Jiaotong University — PHASE4

TrialNOT YET RECRUITING

Dec 2023Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors

IO Biotech — PHASE2

TrialRECRUITING

Apr 2020Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients

Vyriad, Inc. — PHASE2

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Embryonal carcinoma.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Blenoxane

(Bleomycin sulfate)Orphan drugstandard

Bristol-Myers Squibb Pharmaceutical Research Institute

Mechanism of Action Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the i...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Embryonal carcinoma.
Search all trials →

Search clinical trials for Embryonal carcinoma →

Recent News & Research

No recent news articles indexed yet for Embryonal carcinoma.
Search PubMed for Embryonal carcinoma →

Browse all Embryonal carcinoma news →

Specialist Network

Top 6 by expertise

Matthew Krebs, Dr

The Christie Hospital

Score 387 trials

Mikhail Samsonov

R-Pharm

Score 2717 trials

John D. Hainsworth, MD, MD

SCRI Development Innovations, LLC

📍 NASHVILLE, TN

Score 1611 trials

David Hong, MD

M.D. Anderson Cancer Center

Score 95 trials

Joe Y Chang

M.D. Anderson Cancer Center

Score 81 trial188 pubs

James L Gulley, M.D., MD PhD FACP

National Cancer Institute (NCI)

📍 BETHESDA, MD

Score 77 trials

View all Embryonal carcinoma specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰